Rege Nephro Co., Ltd. is a clinical-stage biotech company developing treatments for kidney diseases, including Autosomal Dominant Polycystic Kidney Disease and Chronic Kidney Disease, using technology from Kyoto University's Center for iPS Cell Research and Application.

Shinobi Therapeutics is a biotech company developing off-the-shelf, immune-evasive, induced pluripotent stem cell (iPSC)-derived cell therapies for GPC3+ solid tumor cancers.